EligibleTrials
Conditions › Breast cancer › NCT05933876

The Impact of Radiotherapy on Oligometastatic Cancer

Recruiting · NCT05933876 · Observational (researchers observe without assigning treatment) · Lead sponsor: Institut Investigacio Sanitaria Pere Virgili

View the official record on ClinicalTrials.gov →
Breast cancerLung cancerProstate cancer

Interventions studied

To propose a diagnostic test for Oligometastatic Cancer (OC).To propose a diagnostic test to determine the effectiveness of SABR.To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).

What this trial is about

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

21 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.